• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Narine, N.
    Wallace, A. J.
    Dore, J.
    O'Leary-Jackson, S.
    Al-Najjar, H.
    Bailey, S.
    Khan, K. A.
    Teng, B.
    Qasim, M.
    Shelton, D.
    Holbrook, M.
    Abbasi, S.
    Carter, M.
    Irion, L.
    Al-Habba, S.
    Lindsay, Colin R
    Blackhall, Fiona H
    Rana, D. N.
    Show allShow less
    Affiliation
    Manchester University NHS Foundation Trust. The Christie NHS Foundation Trust.
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Objective: This is a prospective evaluation of ROS1 analysis by IHC against FISH on cytology and small biopsy samples in a routine diagnostic setting and demonstrates both technical and clinical validation. Methods: From 1st March to 31st December 2019, cytology cell blocks and small biopsy samples from a selected cohort of NSCLC patients were concurrently tested for ROS1 gene rearrangement by Vysis 6q22 Break Apart FISH probe and IHC using Cell Signalling D4D6 antibody. Mismatch cases were tested by an RNA fusion NGS panel. Results: In a prospective population of 95 cases, 91 were negative and 2 were positive by both FISH and IHC. Both dual positive cases were female never smokers and benefited from TKI treatment. Another 2 cases were positive by FISH but negative by IHC and repeat by NGS showed one to be negative but one failed. Turnaround time for IHC was 0 to 8 days from request to authorisation whilst that of FISH was 9 to 42 days at a cost of £51 and £159 respectively. Conclusion: IHC to assess for the protein product of ROS1 gene rearrangement on cytology cell blocks and small biopsy samples in a routine setting is a promising screening method to assess eligibility for TKI treatment with positive and indeterminate cases confirmed by FISH or NGS as it has good NPV, faster turnaround time and is cost effective with proven technical and clinical validation
    Citation
    Narine N, Wallace A, Dore J, O’Leary-Jackson S, Al Najjar H, Bailey S, et al. Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. Cytopathology. 2021 Jun 15.
    Journal
    Cytopathology
    URI
    http://hdl.handle.net/10541/624097
    DOI
    10.1111/cyt.12994
    PubMed ID
    34033159
    Additional Links
    https://dx.doi.org/10.1111/cyt.12994
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1111/cyt.12994
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    • Authors: Vlajnic T, Savic S, Barascud A, Baschiera B, Bihl M, Grilli B, Herzog M, Rebetez J, Bubendorf L
    • Issue date: 2018 Jun
    • Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    • Authors: Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC
    • Issue date: 2017 Sep
    • Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
    • Authors: Wu J, Lin Y, He X, Yang H, He P, Fu X, Li G, Gu X
    • Issue date: 2016 Aug 4
    • ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
    • Authors: Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB
    • Issue date: 2022 Apr
    • On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    • Authors: Mescam-Mancini L, Lantuéjoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, Sabourin JC, Decroisette C, Sakhri L, Brambilla E, McLeer-Florin A
    • Issue date: 2014 Feb
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.